$CTGO
Contango ORE, Inc.

2019 Q1 Form 10-Q Financial Statement

#000143774919009655 Filed on May 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q2 2018 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.071M $1.380M $910.0K
YoY Change 17.68% 79.22% 75.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.071M $1.380M $910.0K
YoY Change 17.68% 79.22% 75.0%
Operating Profit
YoY Change
Interest Expense -$364.8K -$2.420M $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.436M -$3.810M -$910.0K
YoY Change 57.77% 394.81% 75.0%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.436M -$3.810M -$906.3K
YoY Change 58.41% 394.81% 75.32%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23 -$0.15
Diluted Earnings Per Share -$0.23 -$621.5K -$0.15
COMMON SHARES
Basic Shares Outstanding 6.357M 6.001M
Diluted Shares Outstanding 6.357M 6.001M

Balance Sheet

Concept 2019 Q1 2018 Q2 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.777M $13.81M $16.65M
YoY Change -41.28% 166.09% 194.69%
Cash & Equivalents $9.777M $13.81M $16.65M
Short-Term Investments
Other Short-Term Assets $197.6K $160.0K $190.0K
YoY Change 3.99% -11.11% 137.5%
Inventory
Prepaid Expenses $197.6K $155.7K $188.8K
Receivables
Other Receivables
Total Short-Term Assets $9.975M $13.97M $16.83M
YoY Change -40.75% 160.2% 193.99%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $9.975M $13.97M $16.83M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $9.975M $13.97M $16.83M
YoY Change -40.75% 160.2% 193.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $151.7K $11.19K $10.50K
YoY Change 1345.08% -77.99% -49.16%
Accrued Expenses $64.19K $245.2K $46.61K
YoY Change 37.71% 183.28% -43.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $215.9K $256.4K $57.11K
YoY Change 278.0% 86.59% -44.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $215.9K $256.4K $57.11K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $215.9K $260.0K $60.00K
YoY Change 259.77% 85.71% -40.0%
SHAREHOLDERS EQUITY
Retained Earnings -$47.51M -$41.30M -$37.50M
YoY Change 26.7% 17.63% 9.19%
Common Stock $57.27M $55.01M $54.27M
YoY Change 5.52% 35.66% 35.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $0.00 $0.00
Shareholders Equity $9.759M $13.71M $16.78M
YoY Change
Total Liabilities & Shareholders Equity $9.975M $13.97M $16.83M
YoY Change -40.75% 160.2% 193.99%

Cashflow Statement

Concept 2019 Q1 2018 Q2 2018 Q1
OPERATING ACTIVITIES
Net Income -$1.436M -$3.810M -$906.3K
YoY Change 58.41% 394.81% 75.32%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$230.8K -$250.0K -$310.0K
YoY Change -25.56% -40.48% 121.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$420.0K -$2.580M
YoY Change
Cash From Investing Activities -$420.0K -$2.580M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 1.130M
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -230.8K -250.0K -310.0K
Cash From Investing Activities -420.0K -2.580M
Cash From Financing Activities 0.000 0.000 1.130M
Net Change In Cash -650.8K -2.830M 820.0K
YoY Change -179.36% 515.22% -685.71%
FREE CASH FLOW
Cash From Operating Activities -$230.8K -$250.0K -$310.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 ctgo Contingent Salary And Compensation Retention Agreement
ContingentSalaryAndCompensationRetentionAgreement
1500000
CY2018Q4 ctgo Equity Method Investment Cumulative Investment
EquityMethodInvestmentCumulativeInvestment
7200000
CY2019Q1 ctgo Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
2
CY2019Q1 ctgo Options And Warrants Outstanding
OptionsAndWarrantsOutstanding
0
CY2018Q2 ctgo Options And Warrants Outstanding
OptionsAndWarrantsOutstanding
35625
ctgo Suspended Losses
SuspendedLosses
23200000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
151676
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
11192
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
64187
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
245212
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
57203269
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54949370
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2255937
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
724970
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2255937
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
731995
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1730112
CY2019Q1 us-gaap Assets
Assets
9975058
CY2018Q2 us-gaap Assets
Assets
13966476
CY2019Q1 us-gaap Assets Current
AssetsCurrent
9975058
CY2018Q2 us-gaap Assets Current
AssetsCurrent
13966476
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> Basis of Presentation</div></div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 24pt; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information, pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;), including instructions to Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-Q and Article <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> of Regulation S-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">X.</div> Accordingly, they do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include all the information and footnotes required by GAAP for complete annual consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair statement of the consolidated financial statements have been included. All such adjustments are of a normal recurring nature. The consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company<div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">&#x2019;s Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the fiscal year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> June&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> The results of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months&nbsp;ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 31, 2019&nbsp;</div>are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of the results that <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>be expected for the fiscal year ending <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> June&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div></div></div></div>
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9777480
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13810805
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5191749
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16645409
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4033325
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11453660
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6357113
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6153266
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6357113
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6153266
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
63571
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
61533
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
1070916
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
906282
us-gaap Costs And Expenses
CostsAndExpenses
3168099
us-gaap Costs And Expenses
CostsAndExpenses
2383262
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.99
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q1 us-gaap Equity Method Investments
EquityMethodInvestments
CY2018Q2 us-gaap Equity Method Investments
EquityMethodInvestments
CY2019Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q1 us-gaap Long Term Debt
LongTermDebt
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12200116
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1070916
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
906282
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3168099
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2383262
CY2019Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-420000
CY2018Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3210000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-40541
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-80313
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
41907
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
12993
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
55232
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
us-gaap Investment Income Interest
InvestmentIncomeInterest
171285
us-gaap Investment Income Interest
InvestmentIncomeInterest
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9975058
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13966476
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
215863
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
256404
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3210000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-823325
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-746456
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1435684
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-906282
us-gaap Net Income Loss
NetIncomeLoss
-6206814
us-gaap Net Income Loss
NetIncomeLoss
-2383262
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
3210000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
197578
CY2018Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
155671
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
12200116
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47507645
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41300831
us-gaap Share Based Compensation
ShareBasedCompensation
2255937
us-gaap Share Based Compensation
ShareBasedCompensation
1730112
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9759195
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
13710072
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: justify; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Management Estimates.</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates</div><div style="display: inline; font-family: Times New Roman, Times, serif; font-size: 10pt;">.</div></div></div></div>
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6357113
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6000946
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6257512
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5523810
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6357113
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6000946
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6257512
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5523810
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6357113
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6000946
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6257512
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5523810

Files In Submission

Name View Source Status
0001437749-19-009655-index-headers.html Edgar Link pending
0001437749-19-009655-index.html Edgar Link pending
0001437749-19-009655.txt Edgar Link pending
0001437749-19-009655-xbrl.zip Edgar Link pending
conta20190331b_10q.htm Edgar Link pending
ctgo-20190331.xml Edgar Link completed
ctgo-20190331.xsd Edgar Link pending
ctgo-20190331_cal.xml Edgar Link unprocessable
ctgo-20190331_def.xml Edgar Link unprocessable
ctgo-20190331_lab.xml Edgar Link unprocessable
ctgo-20190331_pre.xml Edgar Link unprocessable
ex_142180.htm Edgar Link pending
ex_142181.htm Edgar Link pending
ex_142182.htm Edgar Link pending
ex_142183.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gradexthicknessmainpeakandno.jpg Edgar Link pending
phaseicontinuedmap.jpg Edgar Link pending
phaseiiimap.jpg Edgar Link pending
phaseiimapwallholes.jpg Edgar Link pending
phaseimap.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tet18-chiefdannydrill_areasc.jpg Edgar Link pending
tet18-copperhilldrill_areasc.jpg Edgar Link pending